Citations

Showing 10 of 108104 citations.

Single institutional analysis of pancreatic cancer survival trends based on BMI.
Wiisanen, Jeff, McWilliams, Robert R. , Bamlet, William R.

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: 234-234

10.1200/jco.2018.36.4_suppl.234 Get It

234 Background: Body mass index (BMI) has been reported to determine risk for pancreatic cancer in addition to outcome, as those with higher BMI have decreased survival. Since May 2011, therapy for pancreatic cancer has improved with the addition of FOLFIRINOX. This study looks at overall survival in relation to BMI since the advent of the FOLFIRINOX. Methods: 2,277 patients with pancreatic adenocarcinoma were identified through the Mayo Clinic SPORE pancreatic cancer registry from 2000-14. Usual adult and BMI at time of enrollment were utilized as a binary variable ( < 30, ≥30 kg/m2). These were analyzed for association with survival using Kaplan-Meier curves and Cox proportional hazards regression. Results: For the 2000-11 and 2011-14 groups, stage distribution was 4.4%, 34.7%, 21.6%, 39.2% and 1.2%, 39%, 22.2%, 37.6%, respectively for stage 1-4. Since pancreatic cancer commonly causes weight loss, more patients were in the higher usual adult BMI (34.6%) compared to enrollment (17.1%). For the period 2000-11, 33.8% of patients had a usual adult BMI of 30+ vs 37.8% for the 2011-14 patients. As previously reported, there was a difference in survival by BMI for the period 2000-May 2011, however, this was not seen for the period June 2011-14. Conclusions: Based on this cohort of patients, the previously reported detrimental effect of elevated BMI on survival in pancreatic cancer patients is no longer seen. This corresponds with the time period of improvement in pancreatic cancer treatment with FOLFIRINOX. Further studies should be performed to confirm our findings and to identify the causality of this association. [Table: see text]
A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313 (NCT #01959139).
Ramanathan, Ramesh K., McDonough, Shannon, Philip, Philip Agop, Lacy, Jill , Kortmansky, Jeremy , Thumar, Jaykumar , Chiorean, E. Gabriela , Shields, Anthony F. , Behl, Deepti , Mehan, Paul, Gaur, Rakesh , Seery, Tara Elisabeth , Guthrie, Katherine A. , Höchster, Howard S. , Hingorani, Sunil R.

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: 208-208

10.1200/jco.2018.36.4_suppl.208 Get It

208 Background: PEGPH20 degrades hyaluronan (HA), a major component of the stroma, increases delivery of gemcitabine and prolongs survival in preclinical models. We evaluated the activity of PEGPH20 in combination with mFFOX in mPC , unselected for tumor HA. Methods: Pertinent eligibility: untreated mPC, PS of 0-1 and adequate organ function. Standard FFOX was modified to add prophylactic growth factor support and omit bolus 5FU. Due to increased thromboembolic (TE) events with PEGPH20, an amendment instituted LMWH prophylaxis in the PEGPH20 arm only. Following a dose finding cohort of mFFOX + PEGPH20, the Phase II study randomized patients (1:1) to the combination arm or mFFOX alone (n = 138). The primary endpoint was overall survival (OS), with a null median OS of 10 mo and an alternative of 15 mo (1-sided type 1 error 0.1, 80% power). Results: PEGPH20 at 3 mcg/kg, q2 weeks was more tolerable than twice weekly dosing. The randomized phase II study began May 2015. The planned interim futility analysis when 35 deaths occurred gave a HR of 0.44 favoring the standard arm, thus the study was closed to accrual (March 2017). As of August 22, 2017 (n = 111), the estimated median OS in the mFFOX arm was 15.1 mo (95% CI 10.1-15.7) vs 7.6 mo (95% CI 4.6-9.2) in the PEGPH20 arm. Conclusions: OS in the mFFOX control arm (15.1 mo) is longest yet reported. Addition of PEGPH20 to mFFOX is not recommended for further study and appears to be detrimental (HR = 0.48). The impact of PEGPH20 on OS was unexpected and in contrast to favorable results reported for the combination of gemcitabine/nab-paclitaxel + PEGPH20 especially in the HA high cohort (Hingorani S et al. A 4008, ASCO 2017). PEGPH20 with mFFOX caused increased toxicity (mostly GI and TE events) and decreased treatment duration compared to mFFOX alone. Tumor HA content will be analyzed. Funding: NIH/NCI grants CA180888, CA180819; and in part by Halozyme Inc. Clinical trial information: 01959139. [Table: see text]
Dosimetric analysis of distal esophageal adenocarcinoma patients treated by intensity-modulated proton therapy with small spot size.
Liu, Chenbin , Bhangoo, R.S. , Rule, William G., Ross, Helen J. , Paripati, Harshita, Jaroszewski, Dawn E. , Beamer, Staci E. , Fleischer, David E., Ramirez, Francisco C. , Ding, Xiaoning, Ashman, Jonathan B. , Sio, Terence T. , Bues, Martin , Liu, Wei

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: 159-159

10.1200/jco.2018.36.4_suppl.159 Get It

159 Background: Intensity-modulated proton therapy (IMPT) with small spot size has the potential to reduce dose to normal tissues but also introduces new confounding factors such as setup uncertainty, range uncertainty, and interplay effects due to breathing motion. We investigated plan quality and robustness of IMPT with small spot size for distal esophageal adenocarcinoma (DEA). Methods: 19 patients with DEA treated by IMPT were retrospectively evaluated. Spot sizes ranged from 2 to 6mm, with spot spacing of 5mm. All plans were generated using a commercial treatment planning system. In-house-developed dose-evaluation software modeled time-dependent spot delivery to incorporate interplay effects. Dose-volume-histogram (DVH) indices were used to evaluate plan quality and robustness was evaluated using the DVH band method. Results: For plan quality, median values of clinical target volume D95% and D5%-D95% (normalized to the prescribed doses), total lung mean dose, heart mean dose, and cord Dmax were 1.014, 0.035, 3.82Gy[RBE], 7.73Gy[RBE], 39.16Gy[RBE], respectively. For plan robustness, median band widths of the aforementioned DVH indices were 0.018, 0.048, 0.60Gy[RBE], 4.17Gy[RBE], and 2.36Gy[RBE], respectively. For interplay effects, median values of the aforementioned DVH indices were 0.99, 0.061, 4.07Gy[RBE], 7.87Gy[RBE], and 39.66Gy[RBE], respectively. Seven patients underwent esophagectomy after neoadjuvant chemoradiation, and five, three, and one of them achieved downstaging, near complete response, and pathologic complete response, respectively; R0 resection was achieved in all cases. For all patients, acute side effects were mostly limited to grades 1-2 only. The only grade 3 adverse events were related to feeding tube placement (8 patients); there were no RT-induced pneumonitis or other lung-related toxicities. Conclusions: IMPT plans with small spot size for DEA have good target dose coverage, homogeneity and normal tissue protection. Treatment plans are also robust to uncertainties and interplay effects. Early clinical results demonstrate low acute toxicity and encouraging clinical and pathologic response.
Randomized, open-label, phase II study comparing five-weekly S-1 plus cisplatin (SP) with tri-weekly capecitabine plus cisplatin (XP) in chemotherapy-naïve patients with HER2 negative advanced gastric cancer (AGC): OGSG 1105 HERBIS-4A trial.
Takeno, Atsushi , Makari, Youichi, Matsuyama, Jin , Sugimoto, Naotoshi , Taniguchi, Hirokazu , Nagai, Kenichi, Tamura, Shigeyuki , Nishijima, Junichi, Ueda, Shugo , Kimura, Yutaka , Tamura, Takao , Kobayashi, Kenji , Fujitani, Kazumasa , Sakai, Daisuke , Shimokawa, Toshio , Endo, Shunji , Kawabata, Ryohei , Kawakami, Hisato , Kurokawa, Yukinori , Satoh, Taroh

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: 102-102

10.1200/jco.2018.36.4_suppl.102 Get It

102 Background: This phase II study aimed to investigate the safety and efficacy of XP compared to SP in the first-line treatment of HER2 negative AGC. Methods: Patients were randomly assigned to receive either SP (S-1 at 40–60 mg twice daily for 21 days plus cisplatin at 60 mg/ m2 on day 8, every 5 weeks) or XP (capecitabine 1,000 mg/m2 twice daily for 14 days plus cisplatin 80 mg/m2 on day 1, every 3 weeks). Primary endpoint was response rate (RR), and secondary endpoints were progression-free survival (PFS), overall survival (OS), time to treatment failure (TTF), and adverse events. Results: 84 eligible patients were randomly assigned to receive SP ( N = 41) or XP ( N = 43). No statistical difference was observed in overall RR between the SP and XP groups [51.2% (95% CI, 35.1% to 67.1%) vs. 53.5% (95% CI, 37.7% to 68.8%), P = 1.000]. Despite not significant, however, SP vs. XP showed a trend toward better PFS [median, 5.9 months vs. 4.1 months; hazard ratio (HR), 0.763; 95% CI, 0.462 to 1.259; P = .284] and OS (median, 13.5 months vs. 10.0 months; HR, 0.776; 95% CI, 0.485 to 1.244; P = .290). This trend in the SP vs. XP comparison was more pronounced in TTF (median, 4.5 months vs. 3.1 months; HR, 0.651; 95% CI, 0.421 to 1.006; P = .052). Common grade 3 to 4 hematological toxicities were neutropenia and anemia (SP group, 23% and 23%; XP group, 35% and 28%). Grade 3-4 anorexia and hyponatremia were more frequently seen in the XP group (31% and 16%) compared to the SP group (13% and 5%). Treatment-related deaths occurred in one patient (2.3%) in the XP group. Conclusions: XP failed to demonstrate the superior efficacy over SP. Higher incidence of severe toxicities by XP suggests SP as the standard 1st line chemotherapy for HER2 negative AGC in Japan. Clinical trial information: UMIN000006755.
IP 112. Cannabidiol Treatment Effect and Adverse Events in Patients with Lennox–Gastaut’s syndrome: Pooled Results from Two Trials
Privitera, Michael , Bhathal, Hari, Sommerville, Kenneth W. , Roberts, Claire , Cross, J. Helen , Cross, Helen J , Gil‐Nagel, António , Wong, Matthew, Cross, J., Wirrell, Elaine

Mayo Clinic

Neuropediatrics | January 2, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0038-1676030 Get It

Significant Overall Survival Improvement In Proliferative Subtype Ovarian Cancer Patients Receiving Bevacizumab
Kommoss, S, Winterhoff, BJN, Wang, Cangxue, Aliferis, Constantin , Kimmig, Rainer , Wang, Junli , Ma, Sisi , Gregorio, Nikolaus de , Mahner, Sven� , Tourani, Roshan , Park-Simon, TW, Taran, FA, Kommoss, F, Schroeder, W, Dowdy, S.C., Pfisterer, Jacobus , Heitz, Florian , Sehouli, Jalid , Ma, Sisi , Bois, Andreas du , Baumann, K , Schroeder, W., Dowdy, S.C.

Mayo Clinic

Geburtshilfe und Frauenheilkunde | January 2, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0038-1675442 Get It

Heterogeneity of risk within Gleason 4 + 4, 4 + 5 and 5 + 4 prostate cancer
Moschini, Marco , Sharma, Vidit , Soligo, Matteo, Rangel, Laureano J. , Boorjian, Stephen A. , Frank, Igor, Gettman, Matthew T., Thompson, R. Houston, Tollefson, Matthew K. , Karnes, R. Jeffrey , Psutka, Sarah, Rangel, Laureano, Moschini, Marco , Psutka, Sarah P.

Mayo Clinic

Scandinavian Journal of Urology | January 2, 2019 | Volume: 52 | Issue: 5-6 | Pages: 340-348

10.1080/21681805.2018.1534886 | PMID 30600747 Get It

Factors associated with more frequent diagnostic tests and procedures in patients with irritable bowel syndrome
Lacy, Brian E. , Ayyagari, Rajeev , Guérin, Annie , Lopez, Andrea, Shi, Sherry, Luo, Michelle , Guerin, Annie , Lacy, Brian

Mayo Clinic

Therapeutic Advances in Gastroenterology | January 2, 2019 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/1756284818818326 | PMID 30636972 Get It

Background: Irritable bowel syndrome (IBS) reduces quality of life and burdens healthcare systems. This study identified factors associated with frequent use of IBS diagnostic tests and procedures. Methods: Using a United States claims database (2001–2012), tests and procedures in IBS patients occurring in the 2-year study period (12 months before/following the first IBS diagnosis) were analyzed: endoscopy, GI transit testing, anorectal procedures, and radiologic imaging. Patients were classified based on test/procedure frequency (3+, 1–2, or 0). Multivariate logistic regression identified factors associated with more frequent tests/procedures. Results: Among 201,322 IBS patients, 41.7% had 3+ tests/procedures, 35.1% had 1–2, and 23.3% had 0. Patients with more tests/procedures were older [mean age 50.6 (3+ group), more likely to be female and had more comorbidities, including anxiety, depressive disorders, and somatization. Dyspepsia [odds ratio (95% confidence interval): 1.80 (1.72–1.87)], interstitial cystitis [1.60 (1.45–1.77)], gastroesophageal reflux disease [1.59 (1.55–1.63)], constipation [1.50 (1.45–1.54)], and dyspareunia [1.38 (1.25–1.52)] were significantly associated with more tests/procedures (3+ versus 1–2), while anxiety, depressive disorders, and somatization were not. Patients with more frequent specialist visits [emergency department (ED; 1.10 (1.09–1.11)) and gastroenterologists (1.26 (1.26–1.27))] or at least one GI-related ED visit or inpatient admission [1.95 (1.86–2.04) and 3.67 (3.48–3.87), respectively] were more likely to have more tests/procedures (all p < 0.05). Conclusions: Test frequency in patients with IBS is strongly associated with demographic and clinical characteristics, especially comorbid conditions related to IBS. Presence of common overlapping comorbid conditions should increase clinicians’ confidence in making the diagnosis of IBS, thus curtailing redundant testing and reducing healthcare costs.
Editorial Commentary: What Is the Best Graft Source for Posterior Cruciate Ligament Reconstruction?
Martin, R. Kyle , Levy, Bruce A. , Martin, Richard Kyle

Mayo Clinic

Arthroscopy | January 2, 2019 | Volume: 35 | Issue: 1 | Pages: 275-276

10.1016/j.arthro.2018.08.043 | PMID 30611358 Get It

Abstract In 2018, the best available evidence has failed to show any significant clinical or functional difference between autograft and allograft for posterior cruciate ligament reconstruction. Autograft patients may have higher complication rates. Both groups show good functional outcome after reconstruction.